Biosimilars Cut Cancer Drug Costs by Nearly $4,000 a Month for Insurers, UCLA Study Shows
A UCLA-led analysis of more than 14,000 patient-drug pairs published in JAMA Oncology found that exclusive biosimilar use was associated ...
Tag: biosimilars
New Commentary Weighs the Real-World Impact of the First Biosimilar Insulin Glargine
A new letter to the editor in the Journal of General Internal Medicine critically examines real-world evidence on insulin glargine ...
Europe’s Biosimilar Divide: New Study Reveals Which Policies Actually Drive Uptake
A landmark 27-country analysis finds that demand-side policies, especially gain-sharing models and switching programmes, are the strongest levers for boosting ...
Etrasimod First, Upadacitinib Second: Model Names the Most Cost-Effective Ulcerative Colitis Drug Sequence in Japan
A lifetime simulation of 79 drug sequences found that starting with etrasimod and switching to upadacitinib was the most cost-effective ...
First Biosimilar Insulin Glargine Failed to Curb America’s Insulin Spending, Real-World Analysis Finds
A real-world time-series analysis published in the Journal of General Internal Medicine finds that the first biosimilar insulin glargine did ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!